Articles By Estel Grace Masangkay

31. Caprion Posts Positive Data For Plant-Based Flu Vaccine 11/18/2014

    Privately held firm Caprion announced that ImmuneCarta, its immune monitoring business unit, has published positive data from two Phase 1/2 clinical trials of its Virus-like particles (VLPs) vaccine targeting H5 and H1 influenza viruses.

32. AstraZeneca, Isis Ink Deal For Target Delivery Methods In CVMD 11/18/2014

    British giant drug maker AstraZeneca announced that it has entered into strategic alliance with Isis Pharmaceuticals to co-discover and co-develop novel antisense oligonucleotides delivery methods.

33. GSK's New £25M API Plant In Montrose Gets Green Light 11/17/2014

    GlaxoSmithKline’s plans for a new Active Pharmaceutical Ingredient (API) manufacturing facility at its Cobden Street plant in Montrose, U.K., has received approval from the Angus Council.

34. Ascletis Acquires China Rights To Presidio's HCV Drug 11/14/2014

    Biotech firm Ascletis and San Francisco-based clinical-stage pharmaceutical company Presidio Pharmaceuticals announced that they have signed into an exclusive licensing agreement for Presidio’s hepatitis C virus (HCV) drug PPI-668.

35. University Researchers Find 7 New Drug Leads For Blood Cancer 11/13/2014

    A team of scientists from Pondicherry University reported that they have found seven new molecules that could be developed as potent treatments for chronic myelogenous leukemia (CML), a type of blood cancer.

36. Felicitex Therapeutics, Selvita Link Against Cancer Quiescence 11/13/2014

    Cambridge-based Felicitex Therapeutics and Polish biotech firm Selvita announced that the companies have agreed to enter into a collaboration to develop breakthrough personalized cancer drugs against lethal and resistant cancers, including colon, lung, ovarian, pancreatic, and hematopoietic tumors.

37. AstraZeneca's Olaparib Shows Potential In BRCA-Linked Cancers 11/13/2014

    New research from the Abramson Cancer Center of the University of Pennsylvania shows that olaparib, an investigational twice-daily oral cancer drug, has potential in inducing tumor response rate in several advanced cancers associated with BRCA1 and BRCA2 mutations.

38. Genmab, Janssen Link In Daratumumab Phase 3 Study In Myeloma 11/12/2014

    Genmab reported that it has partnered with Janssen Biotech and French Intergroup of Myeloma (IFM) in collaboration with Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) to conduct a Phase 3 trial of daratumumab in frontline multiple myeloma.

39. Perrigo To Buy Omega Pharma For $4.5 Billion 11/12/2014

    Irish consumer healthcare firm Perrigo announced that it will acquire the Belgian OTC healthcare products provider Omega Pharma for $4.5 billion (3.6 billion euros).

40. GSK Files With FDA And EMA For Mepolizumab In Asthma 11/11/2014

    GlaxoSmithKline announced that it has filed regulatory applications with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for mepolizumab as maintenance treatment for severe eosinophilic asthma.